

Cardiac Resynchronization Therapy (CRT)

Phan Minh Huy

Cardiology

University of California – San Diego

Congestive Heart Failure (CHF) in the US


- \approx 5 million have CHF (prevalence)¹
- \approx 550,000 new cases annually (incidence)¹
- HF: most common cardiovascular discharge in elderly patients²
- 25% probability of dying over 2.5 years³
 - 50% of these deaths occur **SUDDENLY (VT/VF)**
 - Despite improvements in medical therapy

¹ American Heart Association. *Heart Disease and Stroke Statistics – 2005 Update*.

² NHLBI, CHF Data Fact Sheet, September 1996.

³ Sweeney MO. *PACE*. 2001;24:871-888.

Magnitude of Sudden Cardiac Arrest (SCA) in the US



¹ American Heart Association. *Heart Disease and Stroke Statistics –2005 Update*.

² Jemel A. *CA Cancer J Clin*. 2003;53:5-26.

³ U.S. *HIV & AIDS Statistic Summary*. Avert.org.

In people diagnosed with heart failure, **sudden cardiac death** occurs at **6-9 times** the rate of the general population


Relationship of SCD and LV Dysfunction

- Reduced left ventricular ejection fraction (LVEF) remains the single most important risk factor for overall mortality and sudden cardiac death¹
- An **ejection fraction $\leq 30\%$** is the single most powerful independent predictor for SCD²


¹ Task Force on Sudden Cardiac Death of the European Society of Cardiology. *Eur Heart J*, 2001;22:1374-1450.

² Myerburg RJ, In Braunwald E, Zipes DP, Libby P, *Heart Disease, A textbook of Cardiovascular Medicine*. 6th ed. Philadelphia: W.B. Saunders, Co. 2001: 895.

LVEF and SCA Incidence



Implantable Cardiac Defibrillator (ICD) reduces SCD



Ventricular Dyssynchrony in Heart Failure

*Left Bundle Branch Block More Prevalent
with Impaired LV Systolic Function*

**Preserved LVSF
(1)**

8%

**Impaired LVSF
(1)**


24%

**Moderate/Severe
HF (2)**




38%

1. Masoudi, et al. JACC 2003;41:217-23

2. Aaronson, et al. Circ 1997;95:2660-7



28/10/2002 13:23:17
T1: 7:54



Deleterious Effects of Ventricular Dyssynchrony

- + Reduced diastolic filling time
- + Weakened contractility
- + Protracted mitral regurgitation
- + Diminished stroke volume


1. Grines CL, et al *Circulation* 1989;79: 845-853
2. Xiao HB, et al *Br Heart J* 1991;66: 443-447
3. Sogaard P, et al. *J Am Coll Cardiol* 2002;40:723–730

Achieving Cardiac Resynchronization

Synchronous biventricular pacing by
transvenous approach for LV lead via
coronary sinus



Medtronic



Medtronic


1954
198
2005

**Right Atrial
Lead**


**Left Ventricular
Lead**

**Right Ventricular
Lead**

10:
30




Cardiac Resynchronization Therapy Randomized Trials




LV Reverse Remodeling after CRT

LV End Systolic and End Diastolic Volumes




Mitral Regurgitation Area



N = 25

MIRACLE Study Program



Source: Abraham, WT et al. AHA 2003


Who Responds to CRT?

Responder Parameter(s)	Finding	Limitation(s)
NYHA III/IV, QRS \geq 130 ms, EF \leq 35%, LVEDD \geq 55 mm	Confirmed in RCTs of over 2,500 patients	<ul style="list-style-type: none"> • ~ 70% respond favorably
QRS \geq 150/155 and/or dP/dt \leq 700 mm Hg/s	Correlated with improved dP/dt ^{1,2}	<ul style="list-style-type: none"> • Small studies, < 30 pts; • No clinical endpoint • Not confirmed by MIRACLE
Difference in time to peak systolic contraction	Correlated with \downarrow volumes ^{3,4,5}	<ul style="list-style-type: none"> • Small studies, \leq 30 pts; • Varying techniques • No clinical endpoint
No MI, significant mitral regurgitation	Correlated with improved NYHA ⁶	<ul style="list-style-type: none"> • Observational study; • Not confirmed by MIRACLE

1. *Circulation*. 2000;101:2703-2709
 2. *Circulation* 1999;99:2993-3001
 3. *Am J Cardiol* 2002;91:684-688

4. *J Am Coll Cardiol* 2002;40:1615-1622
 5. *J Am Coll Cardiol* 2002;40:723-730
 6. *Am J Cardiol* 2002;89:346-350

CMS CRT/CRT-D Coverage Reference Guide



Reference CMS Local Coverage Decision and Bulletins for any specific coverage requirements specific to your region or state. Some local policies require a QRS duration ≥ 130 ms.